TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck: FDA reviewing tablet to eliminate allergy

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

By The Associated Press
Thursday, March 28, 2013, 12:01 a.m.
 

Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that reduces symptoms over time, rather than just temporarily relieving the sneezing and itching.

The treatment, a tablet that dissolves under the tongue, could become the first alternative available in the United States to a long series of uncomfortable allergy shots. Both methods work by gradually desensitizing the patient's immune system to the substance triggering the allergic reaction. Merck's immunotherapy, still unnamed, would be taken daily throughout allergy season.

for three years.

The company, which is based in Whitehouse Station, N.J., also recently applied to the Food and Drug Administration for approval to sell an immunotherapy tablet for ragweed pollen.

Subscribe today! Click here for our subscription offers.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Natural gas industry buys share of Super Bowl spotlight
  2. PPG submits offer for French sealants, adhesives business unit
  3. Super Bowl ads win by playing to viewers’ emotions, experts say
  4. Kennametal plans plant closings, job cuts in fallout from oil and gas decline
  5. Trib 30 stocks drop to four-month low
  6. Wall Street closes January on down note; Dow sheds 251 points
  7. Phelan: Fuel-saving tips for winter driving
  8. Consumer comes to the rescue as companies step back
  9. Obama seeks $215M for precision medicine initiative
  10. BNY Mellon expands  role for treasury exec
  11. Subaru BRZ still needs upgrades